Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Hematology, Oncology and Stem Cell Therapy. 2016; 9 (4): 141-146
en Inglés | IMEMR | ID: emr-184254

RESUMEN

Objective/background: Specific chromosomal translocations are found in human leukemias and lymphomas. These translocations are closely related to particular histological and immunological phenotypes. In Burkitt's lymphoma, translocation t[8;14][q24;q32], which involves the c-myc gene [8q24] and the immunoglobulin heavy-chain [IgH] locus [14q32], accounts for 90-95% of all chromosomal translocations. This translocation can be found in 2-5% of diffuse large B-cell lymphoma [DLBCL]. Long-distance polymerase chain reaction [LD-PCR] assays, which can identify oncogene/Ig gene rearrangement, can detect these fusion genes. The objective of this study was to detect t[8;14] c-myc/IgH gene rearrangement by LD-PCR in patients with DLBCL


Methods: In this study, 54 DLBCL cases were tested by LD-PCR with specific primers. LD-PCR was used for two breakpoints in both the IgH gene [joining region and c switch region] and the myc gene [Exons 2 and 3]


Results: As much as 1.85% of the samples were positive for the c constant region and Exon 2 of the myc gene


Conclusion: LD-PCR can be used for the detection of t[8;14] c-myc/IgH gene rearrangement in patients with DLBCL

2.
AJMB-Avicenna Journal of Medical Biotechnology. 2012; 4 (1): 3-13
en Inglés | IMEMR | ID: emr-163087

RESUMEN

Cell free DNA [cfDNA] is a genetic biomarker that is present in serum or plasma in high concentration in many types of cancer. Identification of circu-lating cancer related DNA molecules in serum or plasma is a non-invasive tool for early diagnosis and prognosis in many cancer patients. For this review, study selection and data extraction were performed by the authors. Detection of point mutations, microsatellite alterations, DNA hypermethylations and losses of heterozygosity in circulating cell free DNA have been characterized in esophagus cancer. Application of circulating cell free DNA as a biomarker, provide the best opportunity for constructing non-invasive tests for early detection, prognosis and management of cancer patients, after therapy in many types of cancer


Asunto(s)
Humanos , Masculino , Femenino , Neoplasias Esofágicas/genética , Biomarcadores de Tumor/genética , Detección Precoz del Cáncer , Pronóstico , Neoplasias Esofágicas/patología , Neoplasias Esofágicas/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA